

CLAIMS

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for the treatment of dermatological disorders comprising:

5 a) a therapeutically effective amount of at least one polypeptide with a terminal sequence KPV;

b) a therapeutically effective amount of an anti-inflammatory agent; and,

c) a carrier.

10 2. The pharmaceutical composition of claim 1 wherein the at least one polypeptide with a terminal sequence KPV is selected from a group consisting of KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing.

15 3. The pharmaceutical composition of claim 1 wherein the anti-inflammatory agent is a glucocorticoid.

4. The pharmaceutical composition of claim 3 wherein the glucocorticoid is selected from the group consisting of beclomethasone dipropionate, betamethasone, cortisone, dexamethasone, fluocinonide, hydrocortisone, methyprednisolone, prednisolone, prednisone, and triamcinolone.

20 5. The pharmaceutical composition of claim 1 wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory drug.

00828372-040601
T09040-2288860

6. The pharmaceutical composition of claim 5 wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of aspirin, diflusal, fenoprofen calcium, ibuprofen, indomethacin, meclofenamate sodium, naproxen, phenylbutazone, piroxicam, sulindac, and tolmetin sodium.

5 7. The pharmaceutical composition of claim 1 wherein the carrier is selected from the group consisting a cream, an ointment, a balm, a foam, a gel, a stick, and a liquid, and combinations thereof.

8. The pharmaceutical composition of claim 7 wherein the carrier has its own medicinal properties.

10 9. The pharmaceutical composition of claim 8 wherein the medicinal properties are selected from the group consisting of emollient properties, analgesic properties, anti-pruritic properties, and soothing properties or combinations thereof.

10. A method of treatment of dermatological disorders comprising:

- 15 a) an administration of a therapeutically effective amount of at least one polypeptide with a terminal sequence KPV;
- b) an administration of a therapeutically effective amount of an anti-inflammatory agent; and
- c) an administration of a carrier.

11. The method of treatment in claim 10 wherein the at least one polypeptide with an
20 terminal sequence KPV is selected from a group consisting of KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3),

12. The method of treatment in claim 10 wherein the anti-inflammatory agent is a glucocorticoid.

14. The method of treatment in claim 10 wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory drug.

15. The method of treatment in claim 14 wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of aspirin, diflusinal, fenoprophén calcium, ibuprophen, indomethacin, meclofenamate sodium, naproxen, phenylbutazone, piroxicam, sulindac, and tolmetin sodium.

15 16. The method of treatment in claim 10 wherein the carrier is selected from the
group consisting a cream, an ointment, a balm, an foam, a gel, a stick, and a liquid, and
combinations thereof.

17. The method of treatment in claim 16 wherein the carrier has its own medicinal properties.

18. The method of treatment in claim 17 wherein the medicinal properties are selected from the group consisting of emollient properties, analgesic properties, anti-pruritic properties, and soothing properties or combinations thereof.

20. A pharmaceutical composition for the prevention of dermatological disorders comprising:

b) a therapeutically effective amount of an anti-inflammatory agent; and,

c) a carrier.

22. The pharmaceutical composition of claim 21 wherein the anti-inflammatory agent is a glucocorticoid.

20 24. The pharmaceutical composition of claim 21 wherein the anti-inflammatory agent
is a non-steroidal anti-inflammatory drug.

25. The pharmaceutical composition of claim 25 wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of aspirin, diflusal, fenoprophene calcium, ibuprofen, indomethacin, meclofenamate sodium, naproxen, phenylbutazone, piroxicam, sulindac, and tolmetin sodium.

5 26. The pharmaceutical composition of claim 21 wherein the carrier is selected from the group consisting of a cream, an ointment, a balm, a foam, a gel, a stick, and a liquid, and combinations thereof.

27. The pharmaceutical composition of claim 27 wherein the carrier has its own medicinal properties.

10 28. The pharmaceutical composition of claim 28 wherein the medicinal properties are selected from the group consisting of emollient properties, analgesic properties, anti-pruritic properties, and soothing properties or combinations thereof.

29. A method of prevention of dermatological disorders comprising:

- 15 a) an administration of a therapeutically effective amount of at least one polypeptide with a terminal sequence KPV;
- b) an administration of a therapeutically effective amount of an anti-inflammatory agent; and
- c) an administration of a carrier.

20 30. The method of treatment in claim 30 wherein the at least one polypeptide with a terminal sequence KPV is selected from the group consisting of KPV (SEQ. ID. NO. 1), MEHFRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3),

SYSMEHFRWGKPV (SEQ. ID. NO. 4), or a biologically functional equivalent of any of the foregoing.

31. The method of treatment in claim 30 wherein the anti-inflammatory agent is a glucocorticoid.

5 32. The method of treatment in claim 32 wherein the glucocorticoid is selected from the group consisting of beclomethasone dipropionate, betamethasone, cortisone, dexamethasone, fluocinonide, hydrocortisone, methyprednisolone, prednisolone, prednisone, and triamcinolone.

10 33. The method of treatment in claim 30 wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory drug.

34. The method of treatment in claim 34 wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of aspirin, diflusal, fenoprophen calcium, ibuprophen, indomethacin, meclofenamate sodium, naproxen, phenylbutazone, piroxicam, sulindac, and tolmetin sodium.

15 35. The method of treatment in claim 30 wherein the carrier is selected from the group consisting a cream, an ointment, a balm, an foam, a gel, a stick, and a liquid, and combinations thereof.

36. The method of treatment in claim 36 wherein the carrier has its own medicinal properties.

20 37. The method of treatment in claim 37 wherein the medicinal properties are selected from the group consisting of emollient properties, analgesic properties, anti-pruritic properties, and soothing properties or combinations thereof.

38. The method of treatment in claim 30 wherein the administration is selected from a group containing topical, nasal, oral, parenteral, and anal.

09823272.040601